正在抓取实时行情...
正在抓取实时行情...
Growth Theme
Innovative drugs and gene editing
US ETFs
3
HK ETFs
0
Theme avg 24h
+0.44%
Growth Thesis
Gene editing, GLP-1, and ADC pipelines drive biotech; XBI and peers offer diversified exposure.
Global innovative drug market projected above $500B by 2030
ETF Picks
Updated 8/27/2026, 12:54:54 AM
| Symbol | Market | Underlying | Price | 24h | Fee | Thesis | Share |
|---|---|---|---|---|---|---|---|
| XBIFeaturedSPDR S&P Biotech | US · NYSE | Equal-weight U.S. biotech | $168 | -0.91% | 0.35% | Equal weighting; small/mid-cap beta | |
| ARKGARK Genomic Revolution | US · CBOE | Gene editing, sequencing, stem cells | $49.17 | +3.02% | 0.75% | ARK genomic revolution thematic fund | |
| IBBiShares Biotechnology | US · NASDAQ | Nasdaq biotechnology | $215.26 | -0.78% | 0.44% | Large-cap biotech; lower vol than XBI |
Refer paid subscribers and earn up to 25% commission. Each successful referral credits your agent account automatically.
Your referral link · ref=JOIN
https://meridianintel.xyz/?ref=JOIN&tenant=meridian-globalPromoter
15%
Silver Agent
20%
Gold Agent
25%